Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsPhase 1

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

fletikumab (NNC109-0012) / Novo Nordisk

NCT01261767: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Terminated

anti-IL-20, placebo

Novo Nordisk A/S

Inflammation, Psoriasis

01/11

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites